A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Los Angeles, California 90045, United States
Palo Alto, California 94304, United States
State College, Pennsylvania 16803, United States
Rosario, Santa Fe, S2002, Argentina
Maroorchydore, Queensland 4558, Australia
Ottawa, Quebec K1H 8L6, Canada
Hangzhou, Zhejiang, 100142, China
Taichung City, 40447, China
Lillie Cedex, 59037, France
Keil, 24105, Germany
Athens, Attiki, 15562, Greece
Hyderabad, Andhra Pradesh 500084, India
Beer Jacob, 73100, Israel
Zapapan, Jalisco 45030, Mexico
Sittard-Geleen, 6162 BG, Netherlands
Ul. Piotrkowska 177, 90-447, Poland
Cape Town, 7500, Senegal
Gauteng, 1820, South Africa
Val de Grace, 0184, South Africa
Majadahonda, Madrid, 28222, Spain
Kozlu, 67000, Taiwan
Niao-Sung Hsiang Kaohsiung County, 83301, Taiwan
Tapei, Beitou Dist., 11217, Taiwan
Izmit/Kocaeli, 41380, Turkey (Türkiye)
Kadiköy/Istanbul, 41380, Turkey (Türkiye)
Zaporizhia, 69063, Ukraine
Corbridge Road, NE46 1QJ, United Kingdom
Lancashire Blackpool, FY3 8NR, United Kingdom
North Manchester Science Park, M15 6SX, United Kingdom